|
|
| 4th In Vivo Cell Engineering & Gene Editing Summit | June 3-5, 2025 | Boston, MA
Join the 4th In Vivo Cell Engineering & Gene Editing Summit, the premier event advancing in vivo cell and gene therapies from research to clinic. Gain exclusive insights into IND-enabling data, regulatory pathways, next-gen delivery, and breakthrough innovations. Hear from leaders like Capstan, Editas, AbbVie & more to stay ahead in oncology, genetic, and rare disease therapies. Learn more. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Here, Shores provides the “who’s who” and “what’s what” behind some of the hottest legal cases to hit the headlines in the mRNA space to-date, as well as why these cases are or could be significant to companies commercializing mRNA products in the future. | |
|
|
|
Achieving cost-effective manufacturing while maintaining high quality standards today is one of the biggest challenges facing companies outsourcing mRNA/RNA development. In turn, panelists Qian Ruan, Andy Geall, and Alex Aust reflect on how and where they’ve seen the costs of mRNA-LNP manufacturing evolving/fluctuating in recent years. |
|
|
|
By Susan Shockey, Clarkston Consulting | The U.S. FDA issued a draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, on January 6, 2025. The public comment period ends April 7. | |
|
|
|
|
| Lipid Nanoparticle Compositional Analysis By UHPLC-CAD | Application Note | MilliporeSigma | Explore results generated from an internal study using a proprietary mRNA-LNP formulation and UHPLC-CAD, a powerful technique for the analysis of compounds that do not contain chromophores. |
|
|
| Ophthalmic Drug Delivery | Article | By Dr. Tamas Solymosi, Nanoform | Examine the challenges to effective delivery of drugs to the eye, intricacies of ophthalmic drug delivery, and advantages of nanoparticles as an enabling technology for ocular drug-delivery systems. |
|
|
|
|
|
|
| Novel Plasmid DNA-Encoded Poly(A) Tails For mRNA Synthesis | Poster | By L. Hinkel, N. Prugar, S. Chilton, O. McPhee, et all., Vernal Biosciences | Here, we evaluate the stability of these variant poly(A) regions and the biological activity of the mRNA containing the variant poly(A) tails made from these templates. |
|
|
| How mRNA Manufacturers Disrupt The Industry | Webinar | Sartorius | Learn how biopharmaceutical companies can apply proven strategies to overcome hidden complexities in mRNA production, and discover solutions that can help you rapidly design and build a SU facility. |
|
|
.png){kind=logo}
